|
|
Post by buyitonsale on Sept 2, 2021 13:54:55 GMT -5
Sell target is always necessary, Unless your long position is imaginary  |
|
|
|
Post by olebob1 on Sept 2, 2021 14:53:19 GMT -5
Sell target is always necessary, Unless your long position is imaginary So sell the News! What is our sell target? |
|
|
|
Post by olebob1 on Sept 2, 2021 14:55:55 GMT -5
Sell target is always necessary, Unless your long position is imaginary So sell the News! What is our sell target? What is your sell target? I don't think I will be able to sell because so many things are in the mix now! |
|
|
|
Post by Clement on Sept 2, 2021 15:44:51 GMT -5
So sell the News! What is our sell target? What is your sell target? I don't think I will be able to sell because so many things are in the mix now! I would sell 10% of my mnkd holdings at 8.30 10% at 10.00 10% at 14.00 10% at 18.00 10% at 22.00 then re-assess. However, the closer we get to the end of October, the more likely I will drop the 8.30 sale. And at anytime I can buy back cheaper after a sale, I will. And I'm watching the options prices for selling covered calls -- not now -- but as the options prices rise. |
|
|
|
Post by buyitonsale on Sept 2, 2021 15:51:15 GMT -5
So sell the News! What is our sell target? What is your sell target? I don't think I will be able to sell because so many things are in the mix now! Every investor should have a sell target, but it is a target based on one's due diligence, cost average, time horizon, expectations and personal situation. My target is not related to any pending news, it is just what is appropriate for me and my position. Of course any major known catalyst matters. For example if my price target is hit before Tyvaso DPI is approved (very unlikely), I would wait until that approval to realize the full potential... My personal target is in double digits, I feel that it is not helpful to anyone if I were to mention a specific number... |
|
|
|
Post by akemp3000 on Sept 2, 2021 17:49:46 GMT -5
I believe there's good advice here on sell targets and strategies but I've been patient longer than ever imagined. Once this thing gets legs with consistent revenue and enters the low double digits, I'm of the opinion this company will merely be arriving at the launching pad for much bigger things to come. I'm staying all in. Oh wait, I just remembered my sales strategy from years ago...I'll sell when Al sells  ' |
|
|
|
Post by olebob1 on Sept 2, 2021 18:36:08 GMT -5
What is your sell target? I don't think I will be able to sell because so many things are in the mix now! I would sell 10% of my mnkd holdings at 8.30 10% at 10.00 10% at 14.00 10% at 18.00 10% at 22.00 then re-assess. However, the closer we get to the end of October, the more likely I will drop the 8.30 sale. And at anytime I can buy back cheaper after a sale, I will. And I'm watching the options prices for selling covered calls -- not now -- but as the options prices rise. Thanks! Nice plan! |
|
|
|
Post by porkini on Sept 2, 2021 18:51:43 GMT -5
What is your sell target? I don't think I will be able to sell because so many things are in the mix now! I would sell 10% of my mnkd holdings at 8.30 10% at 10.00 10% at 14.00 10% at 18.00 10% at 22.00 then re-assess. However, the closer we get to the end of October, the more likely I will drop the 8.30 sale. And at anytime I can buy back cheaper after a sale, I will. And I'm watching the options prices for selling covered calls -- not now -- but as the options prices rise. Just to clarify, is that a 10% @8.30 of 100% holdings, then 10% @10.00 of the original 100% holdings, and so on... OR, would each successive 10% be of the new remaining holdings (so the 10% @10.00 would be 10% of 90% remainder holdings)? The second way you would theoretically not run out of the stock, maybe you would even be fortunate and experience a 1:5 split in the future and regain some shares... I can dream, right? |
|
|
|
Post by longliner on Sept 2, 2021 21:00:18 GMT -5
news.google.com/articles/CAIiECuaqm0ZRujpynxFoAYUtgcqGAgEKg8IACoHCAow1tzJATDnyxUww8rPBg?hl=en-US&gl=US&ceid=US%3AenI believe this is the hedge fund that Brown worked for, while his wife, as head of the FDA (Hamburg) buried us (how Shkreliesk)........first class!  Renaissance paid nearly twice what the Sackler's (Purdue) paid in fines (yesterday) for killing more than 200,000 Americans with opioid's??? Let's hope karma is also extended to the short cartel here. (Now cretin, before you start....I know, no shorts are here).   That was 7 billion...with a B...I'm sure shorts can't afford to lobby here!! We have moderators.
|
|
|
|
Post by nylefty on Sept 3, 2021 0:25:13 GMT -5
I'm not going to sell a share until we reach $20. Then I may sell 10 percent (or maybe not).
|
|
|
|
Post by prcgorman2 on Sept 3, 2021 6:46:40 GMT -5
I like ChrisC’s analysis and agree. Buyout at $25 or more would be acceptable but not desirable and is unlikely.
I also am firmly convinced that the esteemable Dr. Castagna is emotionally and passionately invested in marketing Afrezza for all it is worth. I do not believe for a second that he is satisfied that all that can be done to market Afrezza, has been done. And, I’m right there with him too.
I look at Afrezza as a competitive product with Humalog and Novolog. I don’t mean competitive from a price point. I mean competitive as an insulin for mealtime use. And, I think Humalog and Novolog could become the less-used options and that Afrezza could dominate the market for insulin for prandial (mealtime) use.
I haven’t checked recently to see which categories of drugs make up the dominant portions of the overall BP market, and COVID could be skewing that for now, but last I checked, drugs for treating diabetes edged out drugs for cancer treatment as the front-runner followed by pain medications.
Afrezza, TreT, Zyesami-T, and a migraine medication would be an amazing suite of products in the Mannkind stable. But, my focus was, is, and will be, Afrezza.
|
|
|
|
Post by golfeveryday on Sept 3, 2021 7:00:00 GMT -5
I like ChrisC’s analysis and agree. Buyout at $25 or more would be acceptable but not desirable and is unlikely. I also am firmly convinced that the esteemable Dr. Castagna is emotionally and passionately invested in marketing Afrezza for all it is worth. I do not believe for a second that he is satisfied that all that can be done to market Afrezza, has been done. And, I’m right there with him too. I look at Afrezza as a competitive product with Humalog and Novolog. I don’t mean competitive from a price point. I mean competitive as an insulin for mealtime use. And, I think Humalog and Novolog could become the less-used options and that Afrezza could dominate the market for insulin for prandial (mealtime) use. I haven’t checked recently to see which categories of drugs make up the dominant portions of the overall BP market, and COVID could be skewing that for now, but last I checked, drugs for treating diabetes edged out drugs for cancer treatment as the front-runner followed by pain medications. Afrezza, TreT, Zyesami-T, and a migraine medication would be an amazing suite of products in the Mannkind stable. But, my focus was, is, and will be, Afrezza. maybe MNKD finally gets a partner for the EU for Afrezza and UTHR gets the same EU partner to expand. |
|
|
|
Post by cretin11 on Sept 3, 2021 11:46:03 GMT -5
news.google.com/articles/CAIiECuaqm0ZRujpynxFoAYUtgcqGAgEKg8IACoHCAow1tzJATDnyxUww8rPBg?hl=en-US&gl=US&ceid=US%3AenI believe this is the hedge fund that Brown worked for, while his wife, as head of the FDA (Hamburg) buried us (how Shkreliesk)........first class! Renaissance paid nearly twice what the Sackler's (Purdue) paid in fines (yesterday) for killing more than 200,000 Americans with opioid's??? Let's hope karma is also extended to the short cartel here. (Now cretin, before you start....I know, no shorts are here). That was 7 billion...with a B...I'm sure shorts can't afford to lobby here!! We have moderators. I suppose you’re implying that the linked article is somehow evidence of the “short cartel” infiltrating ProBoards here. That’s a strong imagination at work! Of course they could “afford” to do that, but they simply aren’t choosing to do so here. Sorry to burst your bubble, but please feel free to provide more “evidence” including preferably naming just one or two of the “short cartel” members on this message board. Our moderators apparently haven’t sussed them out so they would probably appreciate the heads up! |
|
|
|
Post by cretin11 on Sept 3, 2021 11:49:47 GMT -5
I also am firmly convinced that the esteemable Dr. Castagna is emotionally and passionately invested in marketing Afrezza for all it is worth. I do not believe for a second that he is satisfied that all that can be done to market Afrezza, has been done. And, I’m right there with him too. That part is hopefully true. There are many of us who agree that not all that can be done to market Afrezza has been done. Not by a long shot. Obviously that’s part of the problem, and many of us are not giving up that we will see some major improvement in that regard. We’d be glad to give credit for learning from past mistakes, if that learning in fact occurs. Fingers crossed. |
|
|
|
Post by mytakeonit on Sept 3, 2021 14:38:00 GMT -5
And I repeat ... MNKD isn't only about Afrezza.
But, that's mytakeonit
|
|
